Product
mRNA-4157
1 clinical trial
1 indication
Indication
MelanomaClinical trial
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)Status: Recruiting, Estimated PCD: 2029-09-09